Influx Healthtech delivered a strong FY26!

Revenue jumped 40% to ₹146.8 Cr, EBITDA surged 45% to ₹29.9 Cr (20.3% margin), and PAT soared 54% to ₹20.5 Cr (14.0% margin). Nutraceuticals fueled 90% of growth.

The company is strategically expanding capacity, aiming for a 2.5x increase, with significant CapEx planned for new facilities in nutraceuticals, veterinary food, and homecare/cosmetics, backed by a ₹10.09 Cr reallocation for expansion.

Recent wins include a 5-year FSSAI license for a new facility, a ₹0.6 Cr tablet capacity boost, and launching Quick Snap™ technology.

They also incorporated Olahey Wellness (₹0.01 Cr) for ready-to-drink beverages and secured entry into Tanzania.

Management targets 25-30% growth in FY27 with stable margins, focusing on commercializing new beverage and pet production lines by H2FY27. #InfluxHealthtech #Financials